Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prazosin HCl
Prazosin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Prazosin Hydrochloride (HCL) 2 milligram (mg) capsule Barceloneta site | ACTIVE_COMPARATOR | One 2 mg capsule manufactured at the current site, Barceloneta |
| Prazosin HCL 2 mg capsule Ascoli site | EXPERIMENTAL | One 2 mg capsule manufactured at the proposed site (Ascoli) |
| Prazosin HCL 1 mg capsule Ascoli site | EXPERIMENTAL | Two 1 mg capsule manufactured at the proposed site, Ascoli |
| Prazosin HCL 5 mg capsule Barceloneta site | ACTIVE_COMPARATOR | One 5 mg capsule manufactured at the current site, Barceloneta |
| Prazosin HCL 1 x 5 mg capsule Ascoli site | ACTIVE_COMPARATOR | One 5 mg capsule manufactured at the proposed site, Ascoli |
| Name | Type | Description |
|---|---|---|
| Prazosin HCl 2mg | DRUG | Prazosin HCL 1 X 2 mg capsule. |
| Prazosin HCl 1 mg | DRUG | Prazosin HCl 2 X 1 mg capsule. |
| Prazosin HCl 5 mg | DRUG | Prazosin HCL 1 X 5 mg capsule. |
Inclusion Criteria: * Participants must be 18 to 55 years of age, inclusive, at the time of signing the Informed Consent Document (ICD). * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, full physical examination, vital signs, 12-l...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Prazosin is a small molecule drug developed by Pfizer, Inc. (ticker: PFE) for hypertension, within the cardiovascular therapeutic area. It is also known as Prazosin HCl or Prazosin HCl 2mg. Prazosin is an investigational product still in clinical development, with Phase 1 trials conducted to date.
Prazosin is being studied for hypertension, a cardiovascular condition. Its clinical trial also listed heart failure among the conditions evaluated. Prazosin has not been approved for marketing based on the development information available, and it remains an investigational therapy in clinical development.
Prazosin targets the alpha-1 adrenergic receptors ADRA1A, ADRA1B, and ADRA1D. It acts as an antagonist at these receptors, meaning it blocks receptor signaling. This target class and receptor profile are the basis for its evaluation in hypertension and related cardiovascular conditions.
Prazosin is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company responsible for the drug's clinical development program, including the Phase 1 bioequivalence study conducted for Prazosin hydrochloride capsules.
Prazosin is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for hypertension or any other indication based on the available development data.
Prazosin has been evaluated in one completed Phase 1 trial, NCT04967443, titled a pivotal bioequivalence study to qualify manufacturing site transfer for Prazosin hydrochloride capsules. The trial enrolled 72 participants in the United States, was randomized and active-controlled, and included healthy volunteers aged 18 years and older.
Yes, Prazosin is also known as Prazosin HCl and Prazosin HCl 2mg. These names refer to the same drug, with HCl indicating the hydrochloride salt form used in the capsules studied in the Phase 1 bioequivalence trial.